Support Advancements in Research


or Use Our Simple Online Form to Give Us Feedback

We welcome your comments and feedback. Please include contact information if you'd like a response.

Did you find this page helpful?

If you would like a response, please include your contact information.

Evangelos S. Gragoudas, M.D.

Harvard Medical School

Charles Edward Whitten Professor of Ophthalmology, Department of Ophthalmology

Massachusetts Eye and Ear

Director, Retina Service
Co-Director, Laser Laboratory
Co-Director, Retina Research Institute
Co-Director, Angiogenesis Laboratory
Senior Scientist

Center Affiliations

Research Summary

Dr. Gragoudas played a pivotal role in the development of proton bean therapy (PBT) for uveal melanoma, and performed both preclinical studies and the first clinical studies in patients. He continues to refine PBT and has taken a multidisciplinary approach to developing new strategies for managing uveal melanoma. Studies initiated in the early 1990s with Dr. Joan Miller produced a breakthrough for patients with wetAMD: photodynamictherapy (PDT) with verteporlin (VISudyne®). He and his colleagues identified the important role of vascular endothelial growth factor (VEGF) in ocular neovascularization, which formed the scientific basis for the present antiangiogenic treatments for neovascular AMD and other intraocular vascular diseases.

Select Publications

For a full publication list, please see his CV.

Proton irradiation for peripapillary and parapapillary melanomas. Lane AM, Kim IK, Gragoudas ES. Arch Ophthalmol. 2011 Sep;129(9):1127-30.

Evaluation of tissue interactions with mechanical elements of a transscleral drug delivery device. Cohen SJ, Chan RVP, Keegan M, Andreoli CM, Borenstein JT, Miller JW, Gragoudas ES. Pharmaceutics. 2012 Mar 12;4(1):212-229.

High throughput mass spectrometry-based mutation profiling of primary uveal melanoma. Daniels AB, Lee JE, MacConaill LE, Pabescandolo E, Hummelen PV, Adams SM, DeAngelis MM, Hahn WC, Gragoudas ES, Harbour W, Garraway LA, Kim IK. Invest. Ophthalmol. Vis. Sci. 2012 Oct 9;53(11): 6991-6996.

Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. Njauw CNJ, Kim I, Piris A, Gabree M, Taylor M, Lane AM, DeAngelis MM, Gragoudas E, Duncan LM, Tsao H. PLOS One. 2012;7(4):e35295.

Aminoimidazole carboxamide ribonucleotide (AICAR) inhibits the growth of retinoblastoma in vivo by decreasing angiogenesis and inducing apoptosis. Theodoropoulou S, Brodowska K, Kayama M, Morizane Y, Miller JW, Gragoudas ES, Vavvas DG. PLoS One. 2013;8(1):e52852.

View a complete list of publications on »  


  • 1965: M.D., Medicine, Athens National & Capodistrian University

Postgraduate Training

  • 1969-1970: Intern, Waltham Hospital
  • 1970-1973: Resident, Ophthalmology, Boston University Affiliated Hospitals
  • 1973-1975: Fellow, Retina, Massachusetts Eye and Ear

Academic Appointments

  • 1975-1978: Instructor in Ophthalmology, Harvard Medical School
  • 1978-1981: Assistant Professor of Ophthalmology, Harvard Medical School
  • 1981-1994: Associate Professor of Ophthalmology, Harvard Medical School
  • 1994-present: Professor of Ophthalmology, Harvard Medical School
  • 2002-2003: Acting Chairman, Department of Ophthalmology, Harvard Medical School
  • 2011-present: Charles Edward Whitten Professor of Ophthalmology, Harvard Medical School

Photo of Evangelos S. Gragoudas, M.D.

Evangelos S. Gragoudas, M.D.


Mass. Eye and Ear

243 Charles Street

Boston, MA 02114

T: 617-573-3515

F: 617-573-3678


For patient inquiries, please visit
» Clinician Profile